Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | FDPS | P14324 | 1/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.40 |
| ▸ | PTPRC | P08575 | 1/20 | 0.40 |
| ▸ | PPID | Q08752 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1831636 | 0.91 | MMP8 (0.61) | MMP8ALDH1A1RECQLPIN1SMN1; SMN2 | |
| SCHEMBL10684512 | 0.91 | MMP8 (0.61) | MMP8ALDH1A1RECQLPIN1SMN1; SMN2 | |
| SCHEMBL604459 | 0.91 | MMP8 (0.61) | MMP8ALDH1A1RECQLPIN1SMN1; SMN2 | |
| SCHEMBL1810261 | 0.89 | PTPN1 (0.51) | MMP8ALDH1A1FDPSSMN1; SMN2HIF1A | |
| SCHEMBL1811459 | 0.88 | CYP3A4 (0.49) | MMP8ALDH1A1RECQLSMN1; SMN2SLC6A2 | |
| SCHEMBL1811750 | 0.86 | FDPS (0.46) | MMP8ALDH1A1RECQLFDPSSMN1; SMN2 | |
| SCHEMBL1806977 | 0.83 | PTPN1 (0.49) | ALDH1A1POLBSLC6A2BLMMEN1 | |
| SCHEMBL1809382 | 0.82 | LMNA (0.43) | ALDH1A1SMN1; SMN2POLBKMT2ALMNA | |
| SCHEMBL1809666 | 0.80 | PTPN1 (0.58) | BLMPTPN1PTPRC | |
| SCHEMBL1773480 | 0.80 | CYP3A4 (0.55) | MMP8ALDH1A1RECQLSMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3904365-A1 | CHEMICAL COMPOUNDS | NuCana plc (GB) | 2021-11-03 | — | — | EP | disclosed |
| US-RE47589-E1 | Phosphoramidate compounds and methods of use | NuCana plc (GB) | 2019-09-03 | — | — | US | disclosed |
| EP-3486251-A1 | CHEMICAL COMPOUNDS | NuCana plc (GB) | 2019-05-22 | — | — | EP | disclosed |
| EP-3040340-B1 | CHEMICAL COMPOUNDS | NuCana plc (GB) | 2018-11-14 | — | — | EP | disclosed |
| EP-2955190-B1 | Chemical compounds | NuCana plc (GB) | 2018-03-28 | — | — | EP | disclosed |
| EP-1646639-B1 | NUCLEOTIDE PHOSPHORAMIDATES AS ANTICANCER AGENTS | NUCANA BIOMED LTD (GB) | 2016-08-17 | — | — | EP | disclosed |
| EP-3040340-A1 | CHEMICAL COMPOUNDS | NuCana BioMed Limited (GB) | 2016-07-06 | — | — | EP | disclosed |
| EP-2955190-A2 | Chemical compounds | NuCana BioMed Limited (GB) | 2015-12-16 | — | — | EP | disclosed |
| US-7951787-B2 | Phosphoramidate compounds and methods of use | CARDIFF PROTIDES LIMITED (GB) | 2011-05-31 | — | — | US | disclosed |
| US-20060142238-A1 | Chemical compounds | NuCana plc (GB) | 2006-06-29 | — | — | US | disclosed |
| EP-1646639-A2 | NUCLEOTIDE PHOSPHORAMIDATES AS ANTICANCER AGENTS | University College Cardiff Consultants, Ltd. (GB) | 2006-04-19 | — | — | EP | disclosed |
| WO-2005012327-A2 | NUCLEOTIDE PHOSPHORAMIDATES AS ANTICANCER AGENTS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142238-A1 | Chemical compounds | NUDT1, DCK, PNP | MMP8 3674/4885ALDH1A1 1643/4885RECQL 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.